
Korean Beauty Start-Ups Bet Booming US Demand Outlasts Tariff Pain
Brands like Tirtir, d'Alba, Torriden and Beauty of Joseon are in talks with major retailers to stock their US shelves, company executives have told Reuters.
Korean beauty, or 'K-beauty,' products are able to compete globally on quality, price and snappy marketing and have benefited greatly from the success of the Asian export giant's other consumer hits, namely its music, film and television.
'K-culture — things like PSY in the past, BTS, and then Korean dramas and films like 'Parasite' — those really paved the way,' Tirtir CEO An Byung-Jun said.
'In the US market, there was already growing interest in South Korea. Then Korean cosmetics entered the scene. The quality was good, but the prices were lower than the existing luxury brands like L'Oréal or Estée Lauder.'
Tirtir's profile shot up last year following the viral online success of its cushion foundation shades designed for dark skin. The product will be sold at some US stores of Ulta Beauty this summer, An told Reuters, adding it aims to double US sales this year.
Retailers in the US from Sephora and Ulta Beauty to Costco and Target are in talks with Korean cosmetics brands to launch sales in their physical stores, according to Reuters' interviews with a dozen people including cosmetics company CEOs, executives and industry experts.
They also expect Korean brands to weather tariffs better than rivals thanks to higher margin business models. Many of them outsource production to contract manufacturers like Cosmax and Kolmar, dubbed the Foxconns of fast beauty, to keep costs down.
South Korea overtook Germany to become the world's third-largest beauty product exporter after France and the US in 2024. Four fifths of its $13 billion cosmetics output are for exports, which have predominantly been driven by e-commerce sales.
Yuliet Mendosa, a 25-year-old visiting Seoul from America, is a fan of K-pop boy band BTS, which led her to greater interest in K-beauty products.
'They go straight to the point to fix what you need to fix and your skin,' she said at an Olive Young store. Changing Landscape
The US push comes at a tricky time for the world's big exporters with President Donald Trump's sweeping tariffs unsettling global trade.
But while the levies create uncertainty for Korea's beauty exporters, strong demand is expected to mitigate some of this, executives say.
South Korea's dominant beauty retailer Olive Young plans to set up its first US store in Los Angeles as early as this year, Jin Se-hoon, Executive Vice President of the company's global platform business, told Reuters.
'The US, especially California, has by far the most customers for our global online shopping platform,' Jin said.
He said Washington's tariffs were a burden but not enough to hurt K-beauty's popularity and value-for-money proposition.
Their US expansion, despite tariffs, also seeks to sustain momentum after exports to China, the biggest overseas market for K-beauty, fell due to geopolitical tensions and competition.
Skincare brand d'Alba, owned by d'Alba Global and known for its vegan mist serum and sunscreens, is in talks with Costco, Ulta Beauty and Target for retail distribution, the company said.
LVMH's cosmetics chain Sephora plans to launch two new Korean brands Torriden and Beauty of Joseon this summer, according to a Sephora spokesperson.
Costco, Target and Ulta did not respond to requests for comments.
Tirtir's An said the baseline 10 percent tariff that the US has already imposed is 'endurable' although the planned 25 percent tariff on South Korean products due in July may force the company to raise prices 'a little bit.'
Seoul, a major US ally, is seeking tariff exemptions in trade talks with Washington.
The Founders — the maker of Anua skincare products, which hit Ulta Beauty shelves this year — also have more room to absorb higher tariffs than rivals, its strategy team leader Jung Jun-ho said. The company posted an operating profit margin of over 30 percent last year. Niche Brands
South Korea replaced France as the biggest cosmetics exporter to the US in 2024, according to official data, driven by online sales through Amazon.
The top five Korean cosmetics brands in US e-commerce — which include Beauty of Joseon, Medicube and Biodance — saw online sales grow 71 percent on average over the past two years, outperforming the overall US market's 21 percent growth, according to Euromonitor data.
The top five French brands — which include L'Oréal Paris, Dior and Lancôme — posted 15 percent growth over that period.
Social media has played a big part in Korea's success.
'Nowadays a single viral TikTok video or influencer endorsement can turn a product into a global bestseller before it even launches outside Korea,' said South Korea-based beauty marketer Odile Monod.
But longer-term success will require increased physical store sales, said Jason Kim, CEO of cosmetics distributor Silicon2.
There are already signs of growth plateauing for some companies, such as startup COSRX, now part of Korean cosmetics giant AmorePacific, as competition heats up and cheaper alternatives emerge, analysts said.
For now, investors remain upbeat about Korean potential, with shares of d'Alba Global more than doubling since their debut last month.
'The K-beauty trend is strong,' Silicon2's Kim said. 'But indie brands will face challenges too.'
By Hyunsu Yim and Hyunjoo Jin; Editing by Miyoung Kim

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Solve the daily Crossword
Yahoo
44 minutes ago
- Yahoo
Exclusive-Shanghai bourse gives bond investors a taste of high yields with new framework, sources say
(Reuters) -The Shanghai Stock Exchange plans to facilitate more companies to issue bonds and attract investors with a new framework for such issuances, two sources said, as China looks to boost funding options for the private sector to revive its economy. Fifty-three bonds worth 37 billion yuan ($5.2 billion) have been sold so far under the new mechanism, which was launched quietly as a pilot late last year, said the sources with direct knowledge of the exchange's scheme. The deals were made possible after the companies under the new framework, which excludes developers and financial firms, were required to make more timely disclosures about businesses, and to bolster measures to protect investors, they added. The aim is to double the issuance number this year, said the sources. Underwriters for these deals have been asked to play a more proactive role in creating demand by facilitating trading of the bonds in the secondary market, said the sources, who declined to be named as they were not authorised to speak to the media. These measures highlight Beijing's efforts to address a mismatch in China's 33 trillion yuan corporate bond market with state enterprises dominating the market. Currently, private issuers account for just 2.4% of China's credit bond market, compared with 95% for state-owned companies, according to Shenwan Hongyuan Securities. Beijing has vowed to broaden the financing pipeline for the private sector, which contributes more than 60% of the economic output and over half of tax revenue, especially as it looks to cushion the impact of Sino-U.S. tensions on the domestic economy. Investors typically do not consider onshore bonds of private firms as an investment option, as they seek safety in notes issued by state-owned enterprises (SOEs) and financial firms, said one of the sources. At the same time, "investors complain of meager yields" offered by state-backed issuers in a low-interest-rate environment, making the Shanghai exchange's new framework a timely move, said the source. The 53 companies, including privately owned conglomerate Nanshan Group and electrical equipment maker TBEA Co, offered coupon rates averaging just shy of 3% - and as much as 4% - for their bonds under the new framework, said the sources. That compares with financing costs of around 2% for big, state-owned issuers. Details of the new framework have not previously been reported. The Shanghai Stock Exchange did not respond to Reuters' request for comment. DEFAULT RISKS The Shanghai bourse arranges frequent virtual and physical roadshows for securities firms, hedge fund houses and wealth managers to better understand the businesses and financial health of the issuers under the initiative, the sources said. The bourse also pushes brokerages to buy the bonds they underwrite and trade the securities in the secondary market to create demand and whet investor appetite for these issuances, they added. Despite the allure of higher returns, some of the investors are not very sanguine about the investment option given the uncertain outlook for private business amid sluggish consumer demand in the world's second-largest economy. Huang Xuefeng, credit research director at Shanghai Anfang Private Fund Co, said his company had bid for some bonds under the new framework, but most of the issuers were not very appealing. "The coupon rates are not super attractive, especially when the issuer is a private company," Huang said. "One would prefer bonds sold by local government financial vehicles, which have few default risks." Huang said that coupon rates higher than 5% by private firms would be enticing, but such pricing could betray financial weakness, potentially discouraging investment by risk-averse institutions. Private companies accounted for 64% of China's bond defaults by value between 2014 and August 2023, according to Shenwan Hongyuan. Investors in China typically do not flock to low-rated, high-yield bonds, compared to the U.S. where the junk bond market is a key segment and has played a pivotal role in financing tech innovations and leveraged buyouts.


Business Insider
an hour ago
- Business Insider
CVX, XOM, SHEL: Oil Prices Recover on News of U.S. Trade Deals and Inventory Decline
Oil prices are recovering as the U.S. announces trade deals with countries such as Japan and reports emerge of a sharp decline in American crude inventories. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Brent crude oil, the international standard, is up 1% and trading at $69.06 a barrel. West Texas Intermediate (WTI) crude, the U.S. benchmark, is also up 1% at $65.91 per barrel. Analysts say that energy markets are now focused on U.S.-European Union trade talks and whether the two powers can reach a negotiated deal before U.S. President Donald Trump's August 1 tariff deadline. A recent trade deal with Japan lowers duties on automotive imports and spares the Asian nation from new levies in exchange for a $550 billion package of investments and loans sent to America. Still, uncertainty over U.S.-China trade negotiations and the ongoing war between Ukraine and Russia are limiting further upside in oil prices, say some analysts. The rise in crude prices is helping to lift the stocks of oil majors such as Chevron (CVX), ExxonMobil (XOM), and Shell (SHEL). Inventories Fall In recent months, WTI crude oil has been range-bound between $60 and $70 a barrel. On the supply side, the U.S. Energy Information Administration has reported that U.S. crude oil inventories fell last week by 3.2 million barrels to a total of 419 million barrels. That decline was greater than the 1.6-million-barrel drawdown expected among analysts. Separately, foreign oil tankers were temporarily prevented from loading at Russia's main Black Sea ports due to new regulations, effectively halting exports from Kazakhstan. And the U.S. government has reiterated that it is considering sanctions on Russian oil to help end the ongoing war in Ukraine. Is CVX Stock a Buy? The stock of Chevron has a consensus Moderate Buy rating among 15 Wall Street analysts. That rating is based on nine Buy, five Hold, and one Sell recommendations assigned in the last three months. The average CVX price target of $164.00 implies 9.30% upside from current levels.